204 related articles for article (PubMed ID: 21706917)
1. Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.
Lu D; Shi HC; Wang ZX; Gu XW; Zeng YJ
Br J Biomed Sci; 2011; 68(2):69-74. PubMed ID: 21706917
[TBL] [Abstract][Full Text] [Related]
2. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
3. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
[TBL] [Abstract][Full Text] [Related]
4. [Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma].
Yu DQ; Yi YF
Ai Zheng; 2003 May; 22(5):496-9. PubMed ID: 12753710
[TBL] [Abstract][Full Text] [Related]
5. [Expression and implication of Pgp, MRP, LRP, GST-pi, Topo II alpha in tongue squamous cell carcinoma].
Leng WD; Wang DZ; Feng G; He J
Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Feb; 22(1):23-5. PubMed ID: 15017692
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.
Sedláková I; Laco J; Caltová K; Červinka M; Tošner J; Řezáč A; Špaček J
Int J Gynecol Cancer; 2015 Feb; 25(2):236-43. PubMed ID: 25594141
[TBL] [Abstract][Full Text] [Related]
7. [The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis].
Cao DY; Shen K; Yang JX; Guan J
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(25):1738-41. PubMed ID: 17919376
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
[TBL] [Abstract][Full Text] [Related]
9. The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer.
Geng M; Wang L; Chen X; Cao R; Li P
Diagn Pathol; 2013 Dec; 8():198. PubMed ID: 24326092
[TBL] [Abstract][Full Text] [Related]
10. [Drug resistance proteins LRP, Pgp, MRP1, MRP3 and MRP5 in ovarian cancer patients].
Sedláková I; Laco J; Tošner J; Spaček J; Cermáková E
Ceska Gynekol; 2013 Dec; 78(6):545-53. PubMed ID: 24372433
[TBL] [Abstract][Full Text] [Related]
11. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
[TBL] [Abstract][Full Text] [Related]
12. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
13. [Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].
Katsaros D; Fracchioli S; Arts HJ; de Vries EG; Danese S; Richiardi G; Arisio R; Gordini G; Van der Zee AG; Suurmeijer AJ; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):463-70. PubMed ID: 10767994
[TBL] [Abstract][Full Text] [Related]
14. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Volm M; Kästel M; Mattern J; Efferth T
Cancer; 1993 Jun; 71(12):3981-7. PubMed ID: 8099529
[TBL] [Abstract][Full Text] [Related]
15. Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer.
Yu P; Du Y; Cheng X; Yu Q; Huang L; Dong R
World J Surg Oncol; 2014 Oct; 12():307. PubMed ID: 25304659
[TBL] [Abstract][Full Text] [Related]
16. [Proteins of resistance and drug resistance in ovarian carcinoma patients].
Sedláková I; Laco J; Tošner J; Caltová K; Cervinka M; Rezáč A; Spaček J; Skapinec P
Klin Onkol; 2012; 25(6):457-63. PubMed ID: 23301649
[TBL] [Abstract][Full Text] [Related]
17. Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance.
Lopes JM; Bruland OS; Bjerkehagen B; Silva MC; Holm R; Pettersen EO; Solheim OP; Sobrinho-Simões M; Nesland JM
Pathol Res Pract; 1997; 193(1):21-36. PubMed ID: 9112270
[TBL] [Abstract][Full Text] [Related]
18. Significance of multidrug resistance gene-related proteins in the postoperative chemotherapy of gastric cancer.
Yu P; Du Y; Yang L; Fan S; Wu J; Zheng S
Int J Clin Exp Pathol; 2014; 7(11):7945-50. PubMed ID: 25550836
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42.
Moran E; Cleary I; Larkin AM; Amhlaoibh RN; Masterson A; Scheper RJ; Izquierdo MA; Center M; O'Sullivan F; Clynes M
Eur J Cancer; 1997 Apr; 33(4):652-60. PubMed ID: 9274450
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival.
Borg AG; Burgess R; Green LM; Scheper RJ; Yin JA
Br J Haematol; 1998 Dec; 103(4):1083-91. PubMed ID: 9886324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]